BT44
BT44 is a novel RET agonist for the treatment of experimental neuropathies.
For research use only. We do not sell to patients.
Chemical Information
| Name | BT44 |
|---|---|
| Iupac Chemical Name | (4-(5-((3,4-Dihydroisoquinolin-2(1H)-yl)sulfonyl)-2-methoxyphenyl)piperazin-1-yl)(4-fluoro-2-(trifluoromethyl)phenyl)methanone |
| Synonyms | BT44; BT-44; BT 44 |
| Molecular Formula | C28H27F4N3O4S |
| Molecular Weight | 577.59 |
| Smile | O=C(N1CCN(C2=CC(S(=O)(N3CC4=C(C=CC=C4)CC3)=O)=CC=C2OC)CC1)C5=CC=C(F)C=C5C(F)(F)F |
| InChiKey | MFQBJWVTKPJNEP-UHFFFAOYSA-N |
| InChi | InChI=1S/C28H27F4N3O4S/c1-39-26-9-7-22(40(37,38)35-11-10-19-4-2-3-5-20(19)18-35)17-25(26)33-12-14-34(15-13-33)27(36)23-8-6-21(29)16-24(23)28(30,31)32/h2-9,16-17H,10-15,18H2,1H3 |
| CAS Number | 924759-42-2 |
| Related CAS |
Ordering Information
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | Solid powder |
|---|---|
| Purity | 98% Min. |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Solubility | Soluble in DMSO |
| Handling | |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| HS Code |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
1: Sverchinsky DV, Nikotina AD, Komarova EY, Mikhaylova ER, Aksenov ND, Lazarev VF, Mitkevich VA, Suezov R, Druzhilovskiy DS, Poroikov VV, Margulis BA, Guzhova IV. Etoposide-Induced Apoptosis in Cancer Cells Can Be Reinforced by an Uncoupled Link between Hsp70 and Caspase-3. Int J Mol Sci. 2018 Aug 25;19(9):2519. doi: 10.3390/ijms19092519. PMID: 30149619; PMCID: PMC6163214.
2: Viisanen H, Nuotio U, Kambur O, Mahato AK, Jokinen V, Lilius T, Li W, Santos HA, Karelson M, Rauhala P, Kalso E, Sidorova YA. Novel RET agonist for the treatment of experimental neuropathies. Mol Pain. 2020 Jan- Dec;16:1744806920950866. doi: 10.1177/1744806920950866. PMID: 32811276.
3: Burr DH, Rollins D, Lee LH, Pattarini DL, Walz SS, Tian JH, Pace JL, Bourgeois AL, Walker RI. Prevention of disease in ferrets fed an inactivated whole cell Campylobacter jejuni vaccine. Vaccine. 2005 Jul 29;23(34):4315-21. doi: 10.1016/j.vaccine.2005.03.038. PMID: 16005742.
4: Hickey TE, Baqar S, Bourgeois AL, Ewing CP, Guerry P. Campylobacter jejuni- stimulated secretion of interleukin-8 by INT407 cells. Infect Immun. 1999 Jan;67(1):88-93. doi: 10.1128/IAI.67.1.88-93.1999. PMID: 9864200; PMCID: PMC96281.
5: McGavock H. Strategies and tactics for effective prescribing during the foundation year. Br J Hosp Med (Lond). 2005 Aug;66(8):Suppl M3-4. doi: 10.12968/hmed.2005.66.Sup1.18523. PMID: 16097522.
Chemical Structure
